SK Pharmteco has announced a $6.1 million investment to expand its Rancho Cordova, California, facility with new lab and kilo-scale capabilities for solid-phase peptide synthesis and purification.
South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.
SK Biopharmaceuticals, a South Korean-based biotech, has announced its new strategy to propel the company towards becoming a global “big biotech.”
South Korean CDMO SK Pharmteco (SKTP) said it will spend $35 million on the initial phase of a planned expansion at the Dublin, Ireland, API site the conglomerate acquired from Bristol Myers Squibb in 2017. Prior to that, SK had been a BMS supplier for around a decade.
